ClinicalTrials.gov record
Recruiting Phase 1 Interventional

First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors

ClinicalTrials.gov ID: NCT05489237

Public ClinicalTrials.gov record NCT05489237. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 5, 2026, 2:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A First-in-human (FIH) Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) [Study ID: StrateGIST 1]

Study identification

NCT ID
NCT05489237
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 1
Lead sponsor
IDRX, Inc., a wholly owned subsidiary of GSK, LLC
Industry
Enrollment
278 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 2, 2022
Primary completion
Mar 9, 2027
Completion
Jun 27, 2028
Last update posted
May 3, 2026

2022 – 2028

United States locations

U.S. sites
8
U.S. states
8
U.S. cities
8
Facility City State ZIP Site status
GSK Investigational Site Miami Florida 33136 Recruiting
GSK Investigational Site Chicago Illinois 60611 Recruiting
GSK Investigational Site Boston Massachusetts 02215 Recruiting
GSK Investigational Site St Louis Missouri 63129 Recruiting
GSK Investigational Site New York New York 10065 Recruiting
GSK Investigational Site Portland Oregon 97239 Recruiting
GSK Investigational Site Philadelphia Pennsylvania 19111 Recruiting
GSK Investigational Site Houston Texas 77030 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 23 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05489237, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 3, 2026 · Synced May 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05489237 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →